Loading company…
QL Biopharm develops and supplies recombinant protein drugs for conditions including diabetes and obesity.
Founded in 2018 and based in Beijing, China, QL Biopharm develops recombinant protein drugs, with a research center in Beijing and a production base in Taizhou. Its pipeline includes 10 innovative and biosimilar candidates for conditions including diabetes, obesity, and non-alcoholic steatohepatitis. In September 2026, it raised nearly CNY 300 million in Series C+ funding led by Cathay Capital, with Huatai Zijin Investment, Tencent Investment, and Elikon Venture participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in